- Industry
- Health and life sciences
- Organization
- Drug Discovery Unit, University of Dundee
- Elad’s role
- Managed small-molecule screening cascades
The business need
The Drug Discovery Unit (DDU) at the University of Dundee runs small-molecule drug discovery programs. Its work on ciliopathies and complex signaling targets needed phenotypic assays, which read a compound's effect from how cells behave, that hold up reproducibly in 384-well high-throughput screening.
What Elad did
- Managed small-molecule screening cascades at the DDU.
- Engineered reproducible 384-well high-throughput phenotypic assays for ciliopathies.
- Engineered assays in the same format for complex signaling targets.
- Co-authored the DDU's published work on topical soft-drug modulators of the S1PR1 receptor (2018 and 2019), a program that started from the oral drug ponesimod, which showed efficacy in a psoriasis trial but caused systemic effects.
Technology and approach
- Reproducible 384-well high-throughput phenotypic assays
Decisions this experience speaks to
- We're building a drug discovery or disease-modelling platform and aren't sure it's compatible with how pharma and biotech customers actually run their screening workflows - how do we find out?
- We have promising preclinical data, but we don't know if it's strong enough, or the right kind of evidence, to support a partnership or licensing conversation?
Related services and use cases
Sources
- Elad Katz’s profile on CTO Grand Rounds
- Discovery of super soft-drug modulators of S1PR1 - University of Dundee Discovery Portal (opens in a new tab)
- Elad Katz, Honorary Research Fellow - University of Dundee Discovery Portal (opens in a new tab)
This case describes Elad Katz’s own work before Grand Rounds, as Elad’s profile and the public sources above describe it. It is not a Grand Rounds engagement and not a promise of the same result for another company.